These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

748 related articles for article (PubMed ID: 32213052)

  • 21. Effectiveness and Safety of Ustekinumab in Ulcerative Colitis: Real-world Evidence from the ENEIDA Registry.
    Chaparro M; Garre A; Iborra M; Sierra-Ausín M; Barreiro-de Acosta M; Fernández-Clotet A; de Castro L; Boscá-Watts M; Casanova MJ; López-García A; Lorente R; Rodríguez C; Carbajo AY; Arroyo MT; Gutiérrez A; Hinojosa J; Martínez-Pérez T; Villoria A; Bermejo F; Busquets D; Camps B; Cañete F; Manceñido N; Monfort D; Navarro-Llavat M; Pérez-Calle JL; Ramos L; Rivero M; Angueira T; Camo Monterde P; Carpio D; García-de-la-Filia I; González-Muñoza C; Hernández L; Huguet JM; Morales VJ; Sicilia B; Vega P; Vera I; Zabana Y; Nos P; Suárez Álvarez P; Calviño-Suárez C; Ricart E; Hernández V; Mínguez M; Márquez L; Hervías Cruz D; Rubio Iturria S; Barrio J; Gargallo-Puyuelo C; Francés R; Hinojosa E; Del Moral M; Calvet X; Algaba A; Aldeguer X; Guardiola J; Mañosa M; Pajares R; Piqueras M; García-Bosch O; López Serrano P; Castro B; Lucendo AJ; Montoro M; Castro Ortiz E; Mesonero F; García-Planella E; Fuentes DA; Bort I; Delgado-Guillena P; Arias L; Iglesias A; Calvo M; Esteve M; Domènech E; Gisbert JP
    J Crohns Colitis; 2021 Nov; 15(11):1846-1851. PubMed ID: 33860795
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Anti-MAdCAM antibody (PF-00547659) for ulcerative colitis (TURANDOT): a phase 2, randomised, double-blind, placebo-controlled trial.
    Vermeire S; Sandborn WJ; Danese S; Hébuterne X; Salzberg BA; Klopocka M; Tarabar D; Vanasek T; Greguš M; Hellstern PA; Kim JS; Sparrow MP; Gorelick KJ; Hinz M; Ahmad A; Pradhan V; Hassan-Zahraee M; Clare R; Cataldi F; Reinisch W
    Lancet; 2017 Jul; 390(10090):135-144. PubMed ID: 28527704
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A critical review of ustekinumab for the treatment of active ulcerative colitis in adults.
    Vieujean S; Louis E; Danese S; Peyrin-Biroulet L
    Expert Rev Gastroenterol Hepatol; 2023 May; 17(5):413-430. PubMed ID: 36949608
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Subcutaneous golimumab maintains clinical response in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):96-109.e1. PubMed ID: 23770005
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study.
    Stallmach A; Langbein C; Atreya R; Bruns T; Dignass A; Ende K; Hampe J; Hartmann F; Neurath MF; Maul J; Preiss JC; Schmelz R; Siegmund B; Schulze H; Teich N; von Arnim U; Baumgart DC; Schmidt C
    Aliment Pharmacol Ther; 2016 Dec; 44(11-12):1199-1212. PubMed ID: 27714831
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
    Danese S; Colombel JF; Lukas M; Gisbert JP; D'Haens G; Hayee B; Panaccione R; Kim HS; Reinisch W; Tyrrell H; Oh YS; Tole S; Chai A; Chamberlain-James K; Tang MT; Schreiber S;
    Lancet Gastroenterol Hepatol; 2022 Feb; 7(2):118-127. PubMed ID: 34798038
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Efficacy and safety of prolonged release budesonide granules in mesalazine-refractory ulcerative colitis: A multi-centre Phase IIa study (TOPICAL-1).
    Fellermann K; Schiefke I; Rácz I; Derova J; Jonaitis L; Wehrum S; Nacak T; Greinwald R
    United European Gastroenterol J; 2020 Dec; 8(10):1186-1195. PubMed ID: 33028169
    [TBL] [Abstract][Full Text] [Related]  

  • 28. One-year outcomes with ustekinumab therapy in infliximab-refractory paediatric ulcerative colitis: a multicentre prospective study.
    Dhaliwal J; McKay HE; Deslandres C; Debruyn J; Wine E; Wu A; Huynh H; Carman N; Crowley E; Church PC; Walters TD; Ricciuto A; Griffiths AM;
    Aliment Pharmacol Ther; 2021 Jun; 53(12):1300-1308. PubMed ID: 33909911
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Early predictors of colectomy and long-term maintenance of remission in ulcerative colitis patients treated using anti-tumour necrosis factor therapy.
    Subramaniam K; Richardson A; Dodd J; Platten J; Shadbolt B; Pavli P
    Intern Med J; 2014 May; 44(5):464-70. PubMed ID: 24612209
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Using Computer Vision to Improve Endoscopic Disease Quantification in Therapeutic Clinical Trials of Ulcerative Colitis.
    Stidham RW; Cai L; Cheng S; Rajaei F; Hiatt T; Wittrup E; Rice MD; Bishu S; Wehkamp J; Schultz W; Khan N; Stojmirovic A; Ghanem LR; Najarian K
    Gastroenterology; 2024 Jan; 166(1):155-167.e2. PubMed ID: 37832924
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Efficacy and safety of induction therapy with calcineurin inhibitors followed by vedolizumab maintenance in 71 patients with severe steroid-refractory ulcerative colitis.
    Ollech JE; Dwadasi S; Rai V; Peleg N; Normatov I; Israel A; Sossenheimer PH; Christensen B; Pekow J; Dalal SR; Sakuraba A; Cohen RD; Rubin DT
    Aliment Pharmacol Ther; 2020 Mar; 51(6):637-643. PubMed ID: 31875986
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Optimization of the treatment with immunosuppressants and biologics in inflammatory bowel disease.
    Renna S; Cottone M; Orlando A
    World J Gastroenterol; 2014 Aug; 20(29):9675-90. PubMed ID: 25110407
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Ustekinumab for treating ulcerative colitis: an expert opinion.
    Biancone L; Ardizzone S; Armuzzi A; Castiglione F; D'Incà R; Danese S; Daperno M; Gionchetti P; Rizzello F; Scribano ML; Vecchi M; Orlando A
    Expert Opin Biol Ther; 2020 Nov; 20(11):1321-1329. PubMed ID: 32662683
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Short-term effectiveness of golimumab for ulcerative colitis: Observational multicenter study.
    Bosca-Watts MM; Cortes X; Iborra M; Huguet JM; Sempere L; Garcia G; Gil R; Garcia M; Muñoz M; Almela P; Maroto N; Paredes JM
    World J Gastroenterol; 2016 Dec; 22(47):10432-10439. PubMed ID: 28058024
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Early Symptomatic Improvement After Ustekinumab Therapy in Patients With Ulcerative Colitis: 16-Week Data From the UNIFI Trial.
    Danese S; Sands BE; Abreu MT; O'Brien CD; Bravatà I; Nazar M; Miao Y; Wang Y; Rowbotham D; Leong RWL; Arasaradnam RP; Afif W; Marano C
    Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2858-2867.e5. PubMed ID: 35276329
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension.
    Abreu MT; Rowbotham DS; Danese S; Sandborn WJ; Miao Y; Zhang H; Tikhonov I; Panaccione R; Hisamatsu T; Scherl EJ; Leong RW; Arasaradnam RP; Afif W; Peyrin-Biroulet L; Sands BE; Marano C
    J Crohns Colitis; 2022 Aug; 16(8):1222-1234. PubMed ID: 35239968
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Subcutaneous golimumab induces clinical response and remission in patients with moderate-to-severe ulcerative colitis.
    Sandborn WJ; Feagan BG; Marano C; Zhang H; Strauss R; Johanns J; Adedokun OJ; Guzzo C; Colombel JF; Reinisch W; Gibson PR; Collins J; Järnerot G; Hibi T; Rutgeerts P;
    Gastroenterology; 2014 Jan; 146(1):85-95; quiz e14-5. PubMed ID: 23735746
    [TBL] [Abstract][Full Text] [Related]  

  • 38. One-year effectiveness and safety of ustekinumab in ulcerative colitis: a multicenter real-world study from Italy.
    Chiappetta MF; Viola A; Mastronardi M; Turchini L; Carparelli S; Orlando A; Biscaglia G; Miranda A; Guida L; Costantino G; Scaldaferri F; Bossa F; Renna S; Cappello M; Alibrandi A; Orlando A; Armuzzi A; Fries W
    Expert Opin Biol Ther; 2021 Nov; 21(11):1483-1489. PubMed ID: 34521307
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Matching-Adjusted Indirect Comparisons of Filgotinib vs Vedolizumab, Tofacitinib, and Ustekinumab for Moderately to Severely Active Ulcerative Colitis.
    Lu X; Zhou ZY; Xin Y; Wang MJ; Gray E; Jairath V; Lindsay JO
    Inflamm Bowel Dis; 2024 Jan; 30(1):64-77. PubMed ID: 36946138
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study.
    Cohen NA; Plevris N; Kopylov U; Grinman A; Ungar B; Yanai H; Leibovitzh H; Isakov NF; Hirsch A; Ritter E; Ron Y; Shitrit AB; Goldin E; Dotan I; Horin SB; Lees CW; Maharshak N
    United European Gastroenterol J; 2020 Nov; 8(9):1076-1085. PubMed ID: 32807038
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 38.